Castor Appoints Andrew Sadler as Chief Product & Technology Officer

NEW YORK–(BUSINESS WIRE)–#biotech—Castor, a leading provider of clinical trial technology to democratize clinical research, today announced the appointment of Andrew Sadler as Chief Product & Technology Officer (CPTO). “Castor’s modular SaaS platform improves the clinical trial experience for patients, sites and sponsors, using technology to accelerate every step of the clinical trial journey,” said Derk … [Read more…]

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

— Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets — — Proof-of-Concept Data Expected in 1Q 2023 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the … [Read more…]

carafem Introduces Telehealth Abortion Care Services in Minnesota

carafem is increasing access to medically supported, at-home abortion care beginning Sept. 27 WASHINGTON–(BUSINESS WIRE)–Client-centered medically supported telehealth abortion care provider, carafem, proudly announces the expansion of telehealth abortion care services to Minnesota – providing people with safe, affordable, high-quality abortion care without the need to travel to a clinic to terminate a pregnancy up … [Read more…]

Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics

Funding is being used to discover and develop a broad pipeline of precision TYK2 therapeutics MENLO PARK, Calif.–(BUSINESS WIRE)–#SeriesA—Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of $37M in Series A financing led by Frazier Life Sciences … [Read more…]

Kaleidoscope Raises $6M Seed Financing Co-Led by Hummingbird Ventures and Dimension

NEW YORK–(BUSINESS WIRE)–#VC—Kaleidoscope, pioneering an operating system to accelerate research team performance, today announced the completion of a $6M seed financing round, co-led by Hummingbird Ventures and Dimension, with participation from Caffeinated Capital, SV Angel, Hawktail, and individual investors. The funding will be used to invest in product development and team expansion, with a focus … [Read more…]

VC Fund Coyote Ventures Raises from Bank of America for Inaugural Fund

Female-led venture fund focuses on startups that are moving the needle on gender equality. SAN FRANCISCO–(BUSINESS WIRE)–Coyote Ventures, a venture firm focused on early-stage women’s health and wellness startups, announced an LP investment from Bank of America today. Led by General Partner Jessica Karr, the firm has already invested in six startups, all of which … [Read more…]

Inmark, a Novvia Group Company, Launches Mobile App for Life Science Packaging

ATLANTA–(BUSINESS WIRE)–Inmark, a Novvia Group Company, unveils a brand-new mobile experience for its Life Science Division. The new app is now available for free download via the Apple App Store or Google Play. The app offers easy on-the-go account & product access for Inmark’s Life Science customers. The app contains access to Inmark’s public online … [Read more…]

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). … [Read more…]

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 – October … [Read more…]

RetinAI Expands Operations with a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies

BERN, Switzerland & BOSTON–(BUSINESS WIRE)–#AI–RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, located in Boston, MA. This expansion will support further growth within the U.S. market, building upon existing collaborations with U.S.-based pharmaceutical … [Read more…]